Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 20, 2010 Rick Aristotle Munarriz	7 More Reasons to Love Earnings Season There are plenty of other prolific companies that are pegged to post year-over-year advances on the bottom line this week: Yahoo!... eBay... Select Comfort... Amazon.com... E*TRADE... UPS... SanDisk...
The Motley Fool November 30, 2006 Rick Aristotle Munarriz	Select Comfort Tosses and Turns The air-mattress maker proves mortal. Until comps resume their growing ways, there may not be a whole lot of life to these shares.
The Motley Fool July 25, 2008 Rick Aristotle Munarriz	Never Take a Stock to Bed Select Comfort beats expectations, but it's all relative, because, on an absolute basis, the quarter was atrocious.
The Motley Fool April 24, 2008 Rick Aristotle Munarriz	Select Comfort: No More Sheep to Count? Select Comfort has a rough night.
The Motley Fool January 13, 2006 Stephen D. Simpson	Once More With Guidant In the ongoing game of tit-for-tat, Boston Scientific ups its bid for Guidant. This battle will ultimately be decided by the 800-pound gorilla that is J&J. Investors, take note.
The Motley Fool December 5, 2005 Stephen D. Simpson	Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note.
The Motley Fool May 25, 2005 Stephen D. Simpson	Stent Wars 2: The Market-Share Menace The battle for drug-coated stent market share between Johnson & Johnson and Boston Scientific may not be as exciting as watching Obi-Wan Kenobi and Anakin Skywalker fight, but the outcome matters for investors.
BusinessWeek January 30, 2006 Robert Barker	Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber.
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
The Motley Fool February 3, 2011 Brian Orelli	Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes.
The Motley Fool February 9, 2007 Rick Aristotle Munarriz	Counting Cheap at Select Comfort The Sleep Number bed maker's got the market's number. Shares inched higher after a better-than-expected fourth-quarter report.
The Motley Fool July 27, 2006 Rick Aristotle Munarriz	Select Comfort Sleeps on It Sales soared high, but the bottom line was even dreamier. Select Comfort is a good bargain for investors right now.
The Motley Fool March 8, 2005 Stephen D. Simpson	The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents.
The Motley Fool December 27, 2006 Rick Aristotle Munarriz	Previewing 2007: Select Comfort If Select Comfort is able to get back into its groove, shares of the company will be a good value at today's prices.
The Motley Fool October 20, 2009 Robert Steyer	The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it.
The Motley Fool April 23, 2008 Brian Orelli	Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up.
The Motley Fool February 12, 2008 Rick Aristotle Munarriz	A Lumpy Mattress Stock Select Comfort shares sank by 31% to a new low, after the company posted disappointing fourth-quarter results.
The Motley Fool June 13, 2006 Jim Mueller	Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool April 13, 2004 Alyce Lomax	J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.
The Motley Fool July 19, 2011 Brian Orelli	J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.
The Motley Fool July 12, 2010 Brian Orelli	Johnson & Johnson MENDs a Hole Another neurovascular device maker, Micrus Endovascular, gets snatched up.
The Motley Fool October 12, 2006 Rick Aristotle Munarriz	Dueling Fools: Select Comfort Bull Investors, sleep better at night with this company.
The Motley Fool October 18, 2010 Anand Chokkavelu	There Are Better Opportunities Than Boston Scientific Let's take a look. By the numbers, Abbott, Medtronic, and Johnson & Johnson all look more compelling than Boston Scientific.
The Motley Fool January 12, 2006 Stephen D. Simpson	The Guidant Auction Continues Johnson & Johnson hopes to save the deal with a last-minute raise of its offer. Although Boston Scientific's offer is $4 per share higher, that doesn't necessarily make it the best value. Investors, take note.
The Motley Fool April 13, 2006 Doug Short	A Foolish Baby Shower: Johnson & Johnson If you're an advocate of these two rules -- "It's never too early to start investing" and "Invest in what you know" -- then here is an ideal pick for baby's first stock.
The Motley Fool October 25, 2007 Rick Aristotle Munarriz	Select Comfort's Worst Nightmare Select Comfort lowers its guidance for the year in advance of quarterly earnings, while rival Tempur-Pedic beats estimates. Investors, take note.
The Motley Fool December 27, 2006 Rick Aristotle Munarriz	2006 in Review: Select Comfort What started out as a good night's sleep got rocky for Select Comfort in 2006. Let's look back to see how events rocked shareholders' slumber.
The Motley Fool October 2, 2008 Brian Orelli	Will Johnson & Johnson Ever Get Its Money? For investors, there are a couple of lessons here. First, perhaps more than any other, the health care sector has a lot of lawsuits.
The Motley Fool July 21, 2010 Brian Orelli	Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now.
The Motley Fool May 19, 2011 G. David Frye	Which Mattress Most Merits Your Investing Cash? Tempur-Pedic gives investors a better night's sleep.
The Motley Fool July 26, 2007 Rick Aristotle Munarriz	Wake Up, Select Comfort! Air mattress maker Select Comfort has another tough quarter. Perhaps they were caught sleeping as competitors moved ahead.
The Motley Fool July 19, 2004 W.D. Crotty	Gold Mine Cave-In? Will recalls involving the Taxus stent mar the future earnings of Boston Scientific?
The Motley Fool November 21, 2006 Ryan Fuhrmann	Shocking Results at Medtronic Favorable earnings boost shares of this medical equipment maker -- but are they too high already?
The Motley Fool January 29, 2009 Brian Orelli	No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed.
The Motley Fool February 24, 2004 Alyce Lomax	J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain?
The Motley Fool February 1, 2010 Brian Orelli	Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost.
The Motley Fool March 16, 2007 Rick Aristotle Munarriz	Bed Bugs at Select Comfort The Sleep Number bed maker holds the line in its mid-quarter update. Investors, take note.
BusinessWeek June 7, 2004 Gene G. Marcial	St. Jude's Bruise Should Clear Up Fast St. Jude Medical (STJ ) tumbled 2%, to $73, after it revealed that the FDA had delayed for a month the approval of its new Epic CRT-defibrillator.
The Motley Fool May 28, 2009 Brian Orelli	Boston Scientific Back in an Atomic Way Can its tiny stent save the day?
The Motley Fool December 13, 2007 Rick Aristotle Munarriz	Select Comfort Lets the Bed Bugs Bite Fitful mattress sales find Select Comfort withdrawing its guidance for both the current quarter and the year ahead, warning that the company will come up short relative to its own initial guidance.
The Motley Fool September 14, 2011 Brian Orelli	How to Muck Up a Turnaround in 12 and a Half Months Boston Scientific's choice for a new CEO has the potential to really muck up its recovery even further -- if that's even possible.
The Motley Fool December 8, 2004 Dave Marino-Nachison	J&J Guided to Guidant? Medical device investors felt their hearts skip as executives told The New York Times the two companies may be set to merge.
The Motley Fool October 25, 2006 Rick Aristotle Munarriz	Select Comfort's Air Ball The bed maker turns the knob higher, despite a rather ordinary start to the second half of the year. Investors, take note.
The Motley Fool September 26, 2005 Stephen D. Simpson	Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors?
The Motley Fool October 29, 2007 Mike Kasprzyk	World's Scariest Stock: Select Comfort Select Comfort is a stock that will keep you tossing and turning at night if you're a shareholder. Only in your dreams will this company earn 50% annual returns.
The Motley Fool June 22, 2005 Stephen D. Simpson	Stent Wars: Jury Strikes Back A jury finds that Boston Scientific has violated J&J's stent patents, but the battle is only beginning. Meanwhile, Boston Scientific continues to have market-share leadership in drug-coated stents and makes quite a bit of money from it.
The Motley Fool February 1, 2005 Stephen D. Simpson	Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth.
The Motley Fool September 30, 2009 Brian Orelli	Boston Scientific Pays Up And Johnson & Johnson reaps the rewards.
The Motley Fool October 14, 2005 Stephen D. Simpson	Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is.